2013-01-15 16:16:43 -
QLogic (Nasdaq: QLGC) $10.18. Today announced it expects to report net revenue of approximately $119 million for the third quarter of fiscal 2013. The expected net revenue exceeds the high end of the previously forecasted third quarter net revenue range of $112 million to $118 million. The preliminary results were driven by higher than expected revenue from Host Products and particularly strong performance from Network Products.
The Company anticipates reporting GAAP income from continuing operations per diluted share for the third quarter of fiscal 2013 in the range of $0.14 to $0.15. On a non-GAAP basis, the Company expects to report income from continuing operations per diluted share in the range of $0.19 to $0.20, above the previously forecasted range of
$0.14 to $0.19 per diluted share. The non-GAAP income from continuing operations per diluted share amount excludes stock-based compensation, acquisition-related charges, and the related income tax effects.
What They Do: QLOgic is a global leader and technology innovator in high performance networking, including adapters, switches and ASICs.
Santarus (Nasdaq: SNTS) $11.28. Announced Monday after market close that the U.S. Food and Drug Administration (FDA) has approved UCERIS (budesonide) extended release tablets for the induction of remission in patients with active, mild to moderate ulcerative colitis. The company expects to commence the commercial launch of UCERIS in March 2013.
UCERIS contains budesonide, a corticosteroid, in a novel oral tablet formulation that utilizes proprietary MMX multi-matrix system colonic delivery technology. The approved dosing regimen for adult patients is one 9 mg tablet taken orally once daily in the morning for up to 8 weeks.
UCERIS was developed in collaboration with Cosmo Technologies Limited, a subsidiary of Cosmo Pharmaceuticals S.p.A.“The FDA approval of UCERIS provides an important new therapeutic option to patients and physicians for the treatment of active, mild to moderate ulcerative colitis,” said William J. Sandborn, M.D., chief, division of Gastroenterology, director, University of California San Diego (UCSD) IBD Center and professor of clinical medicine, UCSD Health System. “Specifically, UCERIS is indicated for use in the induction of remission of active disease, an acute phase of the disease often characterized by cramping, bloating, diarrhea, bleeding, fatigue, weight loss and frequent bowel movements.”
What They Do: Santarus, Inc. is a specialty biopharmaceutical company focused on acquiring, developing and commercializing proprietary products that address the needs of patients treated by physician specialists.
Copyright SmallCapReview. SmallCapReview.com has been a leading site for information on Small Cap Stocks, Penny Stocks and Microcaps since 1999. Visit SmallCapReview.com
to sign up for our FREE newsletter.